Developmental therapeutics
Invited discussant abstracts 125O and 126O
Date
20 Dec 2015Session
Developmental therapeuticsPresenters
Herbert LoongAuthors
H. LoongAuthor affiliations
- Department Of Clinical Oncology, Prince of Wales Hospital, Shatin/HK
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
1143 - First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors
Presenter: Sophie Postel-Vinay
Session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1190 - A phase I study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of AL3810 in advanced solid tumors
Presenter: Athanasios Pallis
Session: Developmental therapeutics
Resources:
Abstract
1304 - Phase 1 study of safety and tolerability of selinexor in Asian patients with advanced solid cancers: updated results
Presenter: Valerie Heong
Session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
743 - Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in Japanese patients with advanced solid tumors
Presenter: Toshio Shimizu
Session: Developmental therapeutics
Resources:
Abstract
1029 - ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models
Presenter: Byoung Chul Cho
Session: Developmental therapeutics
Resources:
Abstract
Invited discussant abstracts 127O and 128O
Presenter: Christian Dittrich
Session: Developmental therapeutics
Resources:
Slides
Webcast
Geographic variations in PK and drug toxicity
Presenter: Alex A. Adjei
Session: Developmental therapeutics
Resources:
Slides
Webcast